MX2018006026A - An a3 adenosine receptor ligand for use in treating ectopic fat accumulation. - Google Patents
An a3 adenosine receptor ligand for use in treating ectopic fat accumulation.Info
- Publication number
- MX2018006026A MX2018006026A MX2018006026A MX2018006026A MX2018006026A MX 2018006026 A MX2018006026 A MX 2018006026A MX 2018006026 A MX2018006026 A MX 2018006026A MX 2018006026 A MX2018006026 A MX 2018006026A MX 2018006026 A MX2018006026 A MX 2018006026A
- Authority
- MX
- Mexico
- Prior art keywords
- fat accumulation
- ligand
- treating
- ectopic fat
- present disclosure
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present disclosure concerns A3AR ligand for reducing ectopic fat accumulation, particularly in fatty liver. Also provided by the present disclosure is the use of A3AR ligand for the preparation of a pharmaceutical composition for reducing such fat accumulation, method of treating a condition associates with fat accumulation making use of the ligand and kits comprising pharmaceutical compositions comprising the ligand, and instructions for use of same, for treating a condition associated with ectopic fat accumulation. In one embodiment, the present disclosure provides the use of an A3AR agonist, such as 2-Chloro-N6-(3-iodobenzyl)-adenosine-5'-N-methyluron amide (C1-IB-MECA, CF102) for treating fatty liver, specifically, non-alcoholic fatty liver disease (NAFLD).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL242723A IL242723B (en) | 2015-11-23 | 2015-11-23 | An a3 adenosine receptor ligand for use in treating ectopic fat accumulation |
| PCT/IL2016/051258 WO2017090036A1 (en) | 2015-11-23 | 2016-11-22 | An a3 adenosine receptor ligand for use in treating ectopic fat accumulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018006026A true MX2018006026A (en) | 2019-01-28 |
Family
ID=57485841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018006026A MX2018006026A (en) | 2015-11-23 | 2016-11-22 | An a3 adenosine receptor ligand for use in treating ectopic fat accumulation. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10780106B2 (en) |
| EP (1) | EP3380104B1 (en) |
| JP (2) | JP6980655B2 (en) |
| KR (1) | KR102103657B1 (en) |
| CN (1) | CN108367016B (en) |
| BR (1) | BR112018010391A8 (en) |
| CA (1) | CA3005961A1 (en) |
| DK (1) | DK3380104T3 (en) |
| ES (1) | ES2848150T3 (en) |
| HR (1) | HRP20210020T1 (en) |
| HU (1) | HUE053558T2 (en) |
| IL (3) | IL242723B (en) |
| LT (1) | LT3380104T (en) |
| MX (1) | MX2018006026A (en) |
| PL (1) | PL3380104T3 (en) |
| PT (1) | PT3380104T (en) |
| RS (1) | RS61372B1 (en) |
| SI (1) | SI3380104T1 (en) |
| WO (1) | WO2017090036A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL254535A0 (en) * | 2017-09-17 | 2017-11-30 | Can Fite Biopharma Ltd | A3 adenosine receptor ligand for managing cytokine release syndrome |
| IL264112A (en) * | 2019-01-06 | 2020-07-30 | Fishman Pnina | An a3 adenosine receptor ligand for use for reducing level of adipocytes |
| IL272078A (en) | 2020-01-16 | 2021-07-29 | Can Fite Biopharma Ltd | Cannabinoids for use in treatment |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5443836A (en) | 1993-03-15 | 1995-08-22 | Gensia, Inc. | Methods for protecting tissues and organs from ischemic damage |
| WO1995002604A1 (en) | 1993-07-13 | 1995-01-26 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor agonists |
| US5688774A (en) | 1993-07-13 | 1997-11-18 | The United States Of America As Represented By The Department Of Health And Human Services | A3 adenosine receptor agonists |
| AU1399297A (en) | 1996-01-24 | 1997-08-20 | Sumitomo Chemical Company, Limited | Dihalopropene compounds, their use as insecticides/acaricides and intermediates for their production |
| US6048865A (en) | 1997-07-29 | 2000-04-11 | Medco Research, Inc. | N6 -substituted-adenosine-5'-uronamides as adenosine receptor modulator |
| JP2003517423A (en) | 1997-07-29 | 2003-05-27 | メドコ リサーチ、インコーポレイテッド | N6-substituted adenosine-5'-uronamide as adenosine receptor modulator |
| AU1363699A (en) | 1997-10-23 | 1999-05-10 | National Institute Of Health | Methods for reducing ischemic injury of the heart via the sequential administ ration of monophosphoryl lipid a and adenosine receptor agents |
| IL133680A0 (en) | 1999-09-10 | 2001-04-30 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
| JP4012070B2 (en) * | 2001-01-16 | 2007-11-21 | カン−フィテ・バイオファーマ・リミテッド | Use of an adenosine A3 receptor agonist to inhibit viral replication |
| DK1983990T3 (en) | 2006-01-26 | 2011-07-11 | Us Gov Health & Human Serv | Allosteric A3 adenosine receptor modulators |
| JP5592262B2 (en) * | 2007-10-15 | 2014-09-17 | キャン−ファイト・バイオファーマ・リミテッド | Method for inducing proliferation of hepatocytes and use thereof |
| CN104159589A (en) * | 2012-01-23 | 2014-11-19 | 坎-菲特生物药物有限公司 | Treatment of liver conditions |
-
2015
- 2015-11-23 IL IL242723A patent/IL242723B/en active IP Right Grant
-
2016
- 2016-11-22 CA CA3005961A patent/CA3005961A1/en active Granted
- 2016-11-22 SI SI201631045T patent/SI3380104T1/en unknown
- 2016-11-22 BR BR112018010391A patent/BR112018010391A8/en not_active Application Discontinuation
- 2016-11-22 WO PCT/IL2016/051258 patent/WO2017090036A1/en active Application Filing
- 2016-11-22 RS RS20210079A patent/RS61372B1/en unknown
- 2016-11-22 KR KR1020187016840A patent/KR102103657B1/en active IP Right Grant
- 2016-11-22 JP JP2018526535A patent/JP6980655B2/en active Active
- 2016-11-22 ES ES16806299T patent/ES2848150T3/en active Active
- 2016-11-22 PL PL16806299T patent/PL3380104T3/en unknown
- 2016-11-22 PT PT168062990T patent/PT3380104T/en unknown
- 2016-11-22 IL IL289841A patent/IL289841B/en unknown
- 2016-11-22 CN CN201680068558.0A patent/CN108367016B/en active Active
- 2016-11-22 HU HUE16806299A patent/HUE053558T2/en unknown
- 2016-11-22 EP EP16806299.0A patent/EP3380104B1/en active Active
- 2016-11-22 DK DK16806299.0T patent/DK3380104T3/en active
- 2016-11-22 MX MX2018006026A patent/MX2018006026A/en unknown
- 2016-11-22 LT LTEP16806299.0T patent/LT3380104T/en unknown
-
2018
- 2018-05-16 IL IL259396A patent/IL259396B/en unknown
- 2018-05-22 US US15/986,332 patent/US10780106B2/en active Active
-
2020
- 2020-02-10 JP JP2020020917A patent/JP6990934B2/en active Active
- 2020-08-26 US US17/003,191 patent/US11291681B2/en active Active
-
2021
- 2021-01-07 HR HRP20210020TT patent/HRP20210020T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017090036A1 (en) | 2017-06-01 |
| EP3380104B1 (en) | 2020-11-11 |
| EP3380104A1 (en) | 2018-10-03 |
| IL289841B (en) | 2022-07-01 |
| CN108367016B (en) | 2021-07-16 |
| DK3380104T3 (en) | 2021-02-08 |
| US10780106B2 (en) | 2020-09-22 |
| US20180264022A1 (en) | 2018-09-20 |
| CN108367016A (en) | 2018-08-03 |
| KR102103657B1 (en) | 2020-04-23 |
| CA3005961A1 (en) | 2017-06-01 |
| US20200384009A1 (en) | 2020-12-10 |
| HUE053558T2 (en) | 2021-07-28 |
| HRP20210020T1 (en) | 2021-03-05 |
| SI3380104T1 (en) | 2021-05-31 |
| US11291681B2 (en) | 2022-04-05 |
| PL3380104T3 (en) | 2021-08-02 |
| LT3380104T (en) | 2021-05-10 |
| PT3380104T (en) | 2021-02-05 |
| KR20180081595A (en) | 2018-07-16 |
| IL242723B (en) | 2019-12-31 |
| JP6980655B2 (en) | 2021-12-15 |
| IL242723A0 (en) | 2016-02-29 |
| RS61372B1 (en) | 2021-02-26 |
| JP2018534333A (en) | 2018-11-22 |
| JP6990934B2 (en) | 2022-01-12 |
| BR112018010391A2 (en) | 2018-11-21 |
| IL289841A (en) | 2022-03-01 |
| IL259396A (en) | 2018-07-31 |
| JP2020090532A (en) | 2020-06-11 |
| BR112018010391A8 (en) | 2019-02-26 |
| IL259396B (en) | 2022-02-01 |
| ES2848150T3 (en) | 2021-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022002771A1 (en) | Affinity matured and humanized antibodies to fcrh5 and their use (cl divisional 201703195). | |
| BR122019026188A8 (en) | METHODS TO DETERMINE WHETHER AN INDIVIDUAL HAS NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), IF A INDIVIDUAL WITH NON-ALCOHOLIC STEETATOSIS HAS NON-ALCOHOLIC STEEATOHEPATITIS, AND TO MONITOR AN INDIVIDUAL WITH NON-ALCOHOLIC STEATOSIS FOR THE DEVELOPMENT OF NASH | |
| CU20190057A7 (en) | COMPOSITIONS INCLUDING AMINO ACIDS | |
| MX2015011690A (en) | Mixed sugar compositions. | |
| WO2016053882A3 (en) | Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers | |
| MX2016014147A (en) | Soluble protein compositions and methods of their making. | |
| MX2018006026A (en) | An a3 adenosine receptor ligand for use in treating ectopic fat accumulation. | |
| EP3285071A4 (en) | Biomarker composition for diagnosing still's disease, diagnostic kit, and diagnostic method | |
| MX2020008125A (en) | Compositions comprising berberine. | |
| WO2019039817A3 (en) | Composition for predicting or diagnosing liver disease, and liver disease prediction or diagnosis method using same | |
| SG11202103646UA (en) | Health-care product composition for enriching asthenic disease, preparation method therefor and use thereof | |
| ZA201705173B (en) | In vitro method for estimating in vivo protein digestibility | |
| WO2016140910A3 (en) | Compositions and methods of using anti-mullerian hormone for treatment of infertility | |
| MX2021013888A (en) | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same. | |
| MX2017009929A (en) | Compositions and methods for improved muscle metabolism. | |
| IL268997B1 (en) | Compositions comprising pgi2-receptor agonists and processes for the preparation thereof | |
| AR097143A1 (en) | MINERAL FOOD COMPOSITION FOR LAMER FOR RUMINANTS AND METHOD TO PREPARE IT | |
| EA201892722A2 (en) | MELASS POWDER AND METHOD FOR ITS PREPARATION | |
| AU2016330230B2 (en) | Low SAFA fat composition, aerated emulsion and method | |
| PH12019502694A1 (en) | Anti-trkb antibodies | |
| EP3304041A4 (en) | Methods of assessing cellular breast samples and compositions for use in practicing the same | |
| MX2019008535A (en) | Pparï agonist for the treatment of huntington's disease. | |
| MX2016002714A (en) | Composition and method of tropicalizing chocolate. | |
| NZ742210A (en) | Neospora vaccine composition | |
| TW201613489A (en) | Hydrolyzed lactose-containing nutritional compositions and uses thereof |